EA005072B1 - Производные пурина, способ их получения и содержащие их фармацевтические композиции - Google Patents

Производные пурина, способ их получения и содержащие их фармацевтические композиции Download PDF

Info

Publication number
EA005072B1
EA005072B1 EA200101224A EA200101224A EA005072B1 EA 005072 B1 EA005072 B1 EA 005072B1 EA 200101224 A EA200101224 A EA 200101224A EA 200101224 A EA200101224 A EA 200101224A EA 005072 B1 EA005072 B1 EA 005072B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
radical
alkyl
compound
carbon atoms
Prior art date
Application number
EA200101224A
Other languages
English (en)
Russian (ru)
Other versions
EA200101224A1 (ru
Inventor
Жан-Люк Асслен
Original Assignee
Авентис Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма С.А. filed Critical Авентис Фарма С.А.
Publication of EA200101224A1 publication Critical patent/EA200101224A1/ru
Publication of EA005072B1 publication Critical patent/EA005072B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200101224A 1999-05-21 2000-05-18 Производные пурина, способ их получения и содержащие их фармацевтические композиции EA005072B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
PCT/FR2000/001335 WO2000071543A1 (fr) 1999-05-21 2000-05-18 Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
EA200101224A1 EA200101224A1 (ru) 2002-10-31
EA005072B1 true EA005072B1 (ru) 2004-10-28

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101224A EA005072B1 (ru) 1999-05-21 2000-05-18 Производные пурина, способ их получения и содержащие их фармацевтические композиции

Country Status (33)

Country Link
US (2) US7122669B1 (enExample)
EP (1) EP1183256B1 (enExample)
JP (1) JP2003500407A (enExample)
KR (1) KR100707895B1 (enExample)
CN (1) CN1298719C (enExample)
AP (1) AP1477A (enExample)
AR (1) AR035317A1 (enExample)
AT (1) ATE370951T1 (enExample)
AU (1) AU4764500A (enExample)
BR (1) BR0011282A (enExample)
CA (1) CA2374714A1 (enExample)
CZ (1) CZ20014163A3 (enExample)
DE (1) DE60036102T2 (enExample)
DK (1) DK1183256T3 (enExample)
DZ (1) DZ3166A1 (enExample)
EA (1) EA005072B1 (enExample)
ES (1) ES2290033T3 (enExample)
FR (1) FR2793794B1 (enExample)
HU (1) HUP0201649A3 (enExample)
IL (1) IL146441A0 (enExample)
MA (1) MA26791A1 (enExample)
MX (1) MXPA01011834A (enExample)
NO (1) NO20015659L (enExample)
NZ (1) NZ515556A (enExample)
PL (1) PL352293A1 (enExample)
PT (1) PT1183256E (enExample)
SK (1) SK16722001A3 (enExample)
TR (1) TR200103349T2 (enExample)
TW (1) TWI284130B (enExample)
UA (1) UA68441C2 (enExample)
WO (1) WO2000071543A1 (enExample)
YU (1) YU86601A (enExample)
ZA (1) ZA200109602B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
EP1377579B1 (en) * 2000-10-31 2009-03-25 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2003301407B2 (en) * 2002-10-15 2010-04-22 Irm Llc Compositions and methods for inducing osteogenesis
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP4086257A1 (en) * 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
CZ308029B6 (cs) 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0841810B1 (en) * 1991-12-05 2000-06-21 Texas Instruments Incorporated Method to improve a video signal
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
EA200101224A1 (ru) 2002-10-31
NZ515556A (en) 2003-08-29
HUP0201649A3 (en) 2003-01-28
US7208598B2 (en) 2007-04-24
UA68441C2 (en) 2004-08-16
YU86601A (sh) 2005-07-19
ATE370951T1 (de) 2007-09-15
TR200103349T2 (tr) 2002-05-21
EP1183256A1 (fr) 2002-03-06
DE60036102T2 (de) 2008-05-15
JP2003500407A (ja) 2003-01-07
ES2290033T3 (es) 2008-02-16
IL146441A0 (en) 2002-07-25
TWI284130B (en) 2007-07-21
DE60036102D1 (de) 2007-10-04
US20050187228A1 (en) 2005-08-25
BR0011282A (pt) 2002-02-26
AP2001002355A0 (en) 2001-12-31
CN1298719C (zh) 2007-02-07
MXPA01011834A (es) 2002-04-17
NO20015659D0 (no) 2001-11-20
PL352293A1 (en) 2003-08-11
ZA200109602B (en) 2003-01-29
NO20015659L (no) 2002-01-18
AP1477A (en) 2005-10-19
US7122669B1 (en) 2006-10-17
CA2374714A1 (fr) 2000-11-30
WO2000071543A1 (fr) 2000-11-30
FR2793794A1 (fr) 2000-11-24
HUP0201649A2 (en) 2002-08-28
MA26791A1 (fr) 2004-12-20
CZ20014163A3 (cs) 2002-10-16
KR20010113975A (ko) 2001-12-28
AU4764500A (en) 2000-12-12
KR100707895B1 (ko) 2007-04-17
PT1183256E (pt) 2007-11-13
CN1361780A (zh) 2002-07-31
DK1183256T3 (da) 2007-12-03
EP1183256B1 (fr) 2007-08-22
SK16722001A3 (sk) 2003-01-09
AR035317A1 (es) 2004-05-12
DZ3166A1 (fr) 2000-11-30
FR2793794B1 (fr) 2001-07-27

Similar Documents

Publication Publication Date Title
CN110546151B (zh) 凋亡诱导剂
EP3565815B1 (en) Compounds as bcl-2-selective apoptosis-inducing agents
KR100707895B1 (ko) 푸린 유도체, 그의 제조 방법 및 이를 함유하는 제약 조성물
JP4084189B2 (ja) 尿素の新誘導体、それらの製造方法、それらの薬剤としての使用、製薬組成物及び新規な用途
ES2805835T3 (es) Compuestos policíclicos como inhibidores de quinasa de tirosina de Bruton
JP2017075155A (ja) Lsd1阻害剤としての(ヘテロ)アリールシクロプロピルアミン化合物
JPS6393755A (ja) アミド誘導体、その製法及びこの化合物を含む肥満症及び関連症治療用医薬組成物
JP2010265272A (ja) ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用
JP2022533740A (ja) メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的bcl-2阻害剤
JP2023552274A (ja) 抗ウイルス化合物としての重水素化アミノチアゾール化合物
JP2006502214A6 (ja) ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用
CN110483487B (zh) 一种2-硫甲基吡唑嘧啶酮类化合物、其制备方法、药物组合物及应用
US20030119876A1 (en) Compounds for the treatment of protozoal diseases
CN105153163A (zh) 2,9-二取代嘌呤-6-氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
CN1328545A (zh) 肼衍生物
RU2782469C2 (ru) Апоптоз-индуцирующие агенты
AU2006202270A1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
HK40093189A (en) Apoptosis-inducing agents
US20230295115A1 (en) Substituted isoquinolinylmethyl amides, analogues thereof, and methods using same
JPH069544A (ja) 中枢神経系抗虚血剤
WO2001087850A1 (en) Pyridazine derivative elevating pdhactivity

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU